Bausch & Lomb is one of the largest vision care companies in the U.S. Bausch spun off from its former parent company, Bausch Health, in 2022 and it now operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals.
As a standalone public company, Bausch now has the ability to freely allocate financial resources to innovate and develop businesses that were underfunded under its former parent company.
Bears
Bausch will face margin pressures from upcoming losses of exclusivity on its pharmaceuticals, and this might hinder its efforts to raise margins to a level comparable with that of its close competitors.
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BLCO is a good fit for your portfolio.
Bausch & Lomb is one of the largest vision care companies in the U.S. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market which B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.